[{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"||GABA receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Engage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Engage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Alprazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Engage Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Engage Therapeutics \/ UCB Pharma S.A"}]

Find Clinical Drug Pipeline Developments & Deals for Alprazolam

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : Staccato alprazolam has demonstrated the ability to rapidly terminate seizures in patients with epilepsy in two minutes or less and prevent recurrence of seizure within two hours.

Product Name : Staccato

Product Type : Controlled Substance

Upfront Cash : Inapplicable

December 03, 2020

Lead Product(s) : Alprazolam

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

World Vaccine Conference
Not Confirmed
World Vaccine Conference
Not Confirmed

Details : The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.

Product Name : Remygen

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 24, 2020

Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam

Therapeutic Area : Endocrinology

Highest Development Status : Phase I/ Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : With is acquisition, UCB will have world-wide rights to Staccato[®] Alprazolam and would perform further clinical development, submission, launch and commercialization of Staccato[®] Alprazolam.

Product Name : Staccato

Product Type : Controlled Substance

Upfront Cash : $125.0 million

May 06, 2020

Lead Product(s) : Alprazolam

Therapeutic Area : Neurology

Highest Development Status : Phase III

Sponsor : UCB Pharma S.A

Deal Size : $270‬.0 million

Deal Type : Acquisition

blank